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ABSTRACT
We have rcportcd that administration of the
phosphodiesterase III inhibitor milrinone increases
renin secretion in conscious rabbits The aim of the
present study was to determine if the increase in renin
secretion results from a direct renal action of
milrinone, or from an indirect extrarenal effect of the
drug. This was accomplished by comparing the effects
ofintrarenal and intravenous infusion of graded doses
ofmilrinone on plasma renin activity in unilaterally
nephrectomized conscious rabbits Milrinone was
infused into the renal artery in doses of 0.01, 0 1 and
1.0 lag/kg/min, and intravenously in the same rabbits in
doses of 0.Ol, 0.1, 1.0 and 10 Iag/kg/min Each dose
was infused for 15 rain No intrarenal dose of
milrinone altered plasma renin activity or arterial
pressure, although at the highest dose, there was a
small increase in heart rate Intravenous infusion of
milrinone at 10 lag/kg/min increased plasma renin
activity to 176 + 55% of the control value (P<0.05).
Heart rate increased but arterial pressure did not
change. Intravenous infusion ofmilrinonc at l0
!ag/kg/min increased plasma renin activity to
386 ± 193% of control in association with a decrease
in arterial pressure and an increase in heart rate. These
results confirm that milrinone increases renin secretion,
and indicate that the stimulation is due to an extrarenal
effect of the drug
i_NTRODUCTIQ_N
It is now generally accepted that cyclic A_AP
plays a major role in the control of renin secretion
Many investigators have reported that beta-
adrenoceptor stimulation, which activates adenylate
cyclase and increases cyclic AMP formation,
stimulates renin secretion in vivo and in ,_itro (I-3).
Renin secretion may also be increased by theophylline
and other methylxanthines which inhibit the hydrolysis
of cyclic AMP by phosphodiesterase (2-4)_ However,
interpretation of this latter finding is complicated by
the fact that methylxanthines exert other actions that
are unrelated to cyclic AMP hydrolysis. For example,
these drugs are known to block adenosine receptors,
and adenosine has been implicated in the regulation of
renin secretion (5)
It is now recognized that phospbodiesterase is
not a single enzyme, but a group of at least five
families ofisozymes (PDE I-V) which differ in their
substrate specificity and regulation (6,7). Specific
inhibiturs of the different isozymes are now available
(6,7), but little information is available concerning
their effects on rcnin secretion. We recently reported
that milrinone, an inhibitor of phosphodiesterase I11,
increases resting renin secretion and enhances the renin
secretory response to beta-adrenoceptor stimulation in
conscious rabbits (8) However, in those experiments,
milrinone was administered systc,nically and it was not
clear if it increased renin secretion by an action in the
kidneys, or by an extrarenal effect. This is an
important distinction because beta-adrenoceptor
stimulation can increase renin secretion by extrarenal
as well as intrarenal actions (9,10).
The aim of the present investigation was to
localize the site of action ofmilrinone on renin
secretion This was accomplished by comparing the
effects of intrarenal and intravenous infusion of graded
doses of the drug on renin secretion in conscious
rabbits.
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MET! IODS
Surgical Procedures
Surgery for unilateral ncphrcctomy and
placement of vascular catheters was performed under
aseptic conditions during anesthesia with intramuscular
ketamine (Parke-Davis, Morris Plains. NJ_ 35-50
mg/kg) and xylazine (Lloyd Laboratories, Shenandoah,
Iowa; 5-10 mg/kg) After surgery, the rabbits were
treated with intravenous ampicillin (Sigma Chemical
Co.. St. Louis. MO; IO rag/day) for at least three days.
Unilateral Nephr¢ctomv
The right kidney was removed using a
retroperitoneal approach by way of a flank incision.
The rabbits were allowed approximately three weeks
to recover from this procedure before surgery for
catheter placement.
Vascular Catheters
The left renal and adrcnal artcrics wcre
exposed by way of a flank incision A catheter
consisting of PEl0 tubing was inserted into the left
adrenal artery and advancec_ into the left. renal artery.
Another catheter consisting of 10 cm of medical grade
Silastic (Dow-Corning Corp.. Midland, MI) connected
to PE60 tubing was inserted into a femoral artery and
advanced into the aorta to a point distal to the kidneys.
Two Tygon catheters were inserted into a jugular vein
and positioned near the heart All catheters were led
subcutaneously to a point between the scapulae where
they emerged through a small skin incision and were
protected in a pocket of a nylon mesh jacket The
rabbits were allowed to recover for at least three days
following this procedure, during which time they were
brought to the laboratory and accustomed to the
experimental environment. The catheters were flushed
with sterile heparinized isotonic saline ( 1000 U/ml) at
least every other day. Using this preparation, it was
possible to compare the effects of intrarenal and
intravenous infusion ofmilrinone in the same animals.
Moreover, because the infused kidney was the only
kidney present, systemic arterial plasma renin activity
could be used as an index of the rate of renln secretion
by that kidney.
Experimental Procedures
On the day of an experiment, rabbits were
brought to the laboratory and placed in a partly
covered cage. Arterial blood pressure and heart rate
were continuously monitored using a pressure
transducer (Cobe Laboratories, Inc., Lakewood, CO)
and a custom-built cardiovascular analyzer, and
recorded on a Grass polygraph. Blood samples for
analysis (volume = 1.2 ml) were collected from the
femoral arterial catheter and replaced with an equal
volume of sterile isotonic NaCI. Experiments were
begun when blood pressure and heart rate had
remained stable at their basal values for at least
15 min
Effects of Intrarenal and lmr_.venous Milrinone
Blood pressure and heart rate were recorded
during a 15 rain control period at the end of which an
arterial blood sample was collected. The
phosphodiesterase 111inhibitor milrinone 0arimacor,
Sanofi Winthrop Pharmaceuticals, New York, NY)
was then infused into the left renal artery in a dose of
0.01 _tg/kg/min for 15 rain. The dose was then
increased to 0.1 lag/kg/min, and after another 15 min,
to t.0 lag/kg/min. Blood samples were collected at the
end of each 15-rain infusion period. After a 30-min
recovery period, the same procedure was repeated
except that milrinone was infused intravenously
instead of into the renal artery. Because each kidney
normally receives approximately 10% of the cardiac
output, the concentration of milrinone in the renal
circulation during intravenous infusion would only be
10% of that during intrarenal infusion. Therefore, the
effect of a higher intravenous dose of milrinone, 10
lag/kg/min, was also tested.
Plasma Renin Activity
Plasma renin activity was measured using a
radioimmunoassay for angiotensin I, and expressed as
nanograms angiotensin I generated per ml plasma
during a two-hour incubation at 37 ° C and pH 6.5
(ng/ml/2h) (1 l).
Statistical Analysis
Results are expressed as the mean ± SE
Data were analyzed using analysis of variance for
repeated measures (ANOVA) (12). When significant
changes were detected by ANOVA, Dunnett's test
(12) was used to make comparisons with the pre-
infusion control value. Changes were considered to be
statistically significant when P < 0.05.
RESULTS
The effects of all intrarenal and intravenous
doses of milrinone on blood pressure, heart rate and
plasma retain activity were tested in each of three
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FIGURE 1.
Effects ofintrarenal and intravenous infusion of
milrinone on mean arterial pressure, heart rate and
plasma renin activity. Plasma renin activity is
expressed as a percentage of the initial control value
(165 4- 8.4 ng/ml/2h). Results are expressed as the
mean and standard error of observations made in three
conscious rabbits.
* P<0.05 compared to the corresponding control
value.
rabbits The data are summarized in Figure 1 Note
that plasma renin activity is expressed as a percentage
of the initial control value which averaged 16.5 ± 8.4
ng/ml/2h Mean arterial pressure and plasma renin
activity did not change significantly during intrarenal
infusion of any dose of milrinone, but there was a
small increase in heart rate from 244 ± 4 to 265 4- 5
beats/min during infusion of'the highest dose (P<005)
Intravenous infusion of the lowest two doses of
milrinone did not change any of the measured
variables. Infusion at 1.0 gg/kg/min did not
significantly change mean arterial pressure, but
increased heart rate from 273 + 7 to 286 4- 11
beats/min (P<0.05) and plasma renin activity to
t76 4- 55% of control (P<0.05) Infusion at 10
lag/kg/min decreased mean arterial pressure from
90 4- 7 to 81 ± 10 mm Hg (P<0 05), increased heart
rate from 273 ± 7 to 302 4- 11 beats/min (P<0.05), and
increased plasma renin activity to 386 ± 193°/, of
control (P<0.05).
DISCUSSION
Cyclic AMP is known to play an important role
in the control ofrenin secretion According to current
concepts, renin secretion increases when cyclic AMP
formation in the juxtaglomerular cells is increased by
stimulating adenylate cyclase, or x_,hen cyclic AMP
hydrolysis is decreased by inhibiting phosphodiesterase
(1-3).
Phosphodiesterase is not a single enzyme, but a
group of families ofisozymes which differ in their
substrate specificity and regulation by cyclic
nucleotides and other factors (6,7). However, little
information is available concerning the role of these
enzymes in the control of tenth secretion The effects
of some phosphodiesterase inhibitors on renin
secretion have been investigated in patients with heart
failure, but variable results have been obtained (13-
16).
Recently we observed that administration of
the phosphodiesterase III inhibitor milrinone stimulates
renin secretion in conscious rabbits (8). llo_vever,
because the milrinone was infused intravenously, it
was not clear if it increased renin secretion directly by
an action in the kidney, or indirectly by an extrarenal
effect of the drug. The aim of the present
investigation was to localize the site of action of
milrinone on renin secretion by comparing the effects
of intrarenal and intravenous infusion of graded doses
ofmilrinone The experiments were performed in
conscious rabbits to avoid thc confounding cffcct of
anesthesia on renin secretion (2), and the effects of
intrarenal and intravenous milrinone were studied
under identical conditions in the same rabbits
Intravenous infusion of the highest two doses
of milrinone, 1 0 and 10 lag/kg/min, increased plasma
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renin activity to 176 and 386% of control respectively.
On the other hand, intrarenal infusion of milrinone at
0.1 and I 0 lag/kg/min did not change plasma renin
activity. Since each kidney normally receives
approximately 10% of the cardiac output, the
intrarenal infusion ofmilrinone at 0.1 and 1.0
)sg,'kg/min would have produced approximately the
same increases in renal arterial milrinone concentration
as intravenous infusion at 1.0 and 10 lag/kg/min
respectively. These results therefore indicate that
milrinone increases renin secretion by an extrarenal
effect, rather than by a direct action on the kidney.
The mechanism by which intravenous
administration of milrinone increases renin secretion
remains to be determined The highest intravenous
dose of milrinone decreased arterial pressure and this
may have contributed to the increase in renin
secretion However, other factors are apparently
involved since in a previous study in a larger group of
rabbits we observed that the same dose of milrinone
increased plasma ronin activity without decreasing
blood pressure (8). Moreover, in the present study,
intravenous infusion of milrinone at 10 )_g/kg/min also
increased plasma renin activity without decreasing
blood pressure.
We (9) and others (I 0) have previously
described an extrarenal effect ofbeta-adrenoceptor
stimulation on renin secretion. Ahhough the
mechanisms and pathways involved have not been fully
elucidated, it is likely that this extrarcnal cffcct ofbeta-
adrenoceptor stimulation, like the intrarenal action, is
mediated by an increase in cyclic AMP concentratior,.
Milrinone could mimic this effect by suppressing the
hydrolysis of cyclic AMP at the extrarenal site.
Finally it is worth pointing out that
phosphodiesterase III isozymes are inhibitable by
cyclic GMP (6,7) This is of potential importance
since guanylate cyclase is a major target for nitric
oxide (17,18), which has recently been implicated in
the control of renin secretion. For example, several
investigators have reported that drugs which increase
or decrease nitric oxide levels cause marked alterations
in renin seretion (19-22). it is possible Ihat these nitric
oxide-induced changes in retain secretion are due, at
least in part, to alterations in cyclic AMP metabolism.
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